The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.

The reader should not assume that the information is accurate and complete.

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM D

Notice of Exempt Offering of Securities

OMB APPROVAL

**OMB** 3235-Number: 0076

Estimated average

burden

hours per

4.00 response:

1. Issuer's Identity

**CIK (Filer ID Number)** 

**Previous** X None **Names** 

**Entity Type** 

0001070494

Name of Issuer

X Corporation

Limited Partnership

ACADIA PHARMACEUTICALS INC

Limited Liability Company General Partnership

Jurisdiction of **Incorporation/Organization** 

**Business Trust** 

Other (Specify)

**DELAWARE** 

Year of Incorporation/Organization

X Over Five Years Ago

Within Last Five Years (Specify Year)

Yet to Be Formed

2. Principal Place of Business and Contact Information

Name of Issuer

ACADIA PHARMACEUTICALS INC

**Street Address 1 Street Address 2** 

3911 SORRENTO VALLEY BLVD

**State/Province/Country** ZIP/PostalCode Phone Number of Issuer City

SAN DIEGO **CALIFORNIA** 92121 858-558-2871

3. Related Persons

**Last Name** First Name Middle Name

**HACKSELL** ULI

> **Street Address 1** Street Address 2

3911 SORRENTO VALLEY BLVD

State/Province/Country ZIP/PostalCode City

SAN DIEGO **CALIFORNIA** 92121

**Relationship:** X Executive Officer X Director Promoter

Clarification of Response (if Necessary):

**Last Name** First Name Middle Name

**BREGE LAURA** Α

> **Street Address 1** Street Address 2

C/O ACADIA

3911 SORRENTO VALLEY BLVD PHARMACEUTICALS INC.

> City State/Province/Country ZIP/PostalCode

SAN DIEGO **CALIFORNIA** 92121

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

**Last Name First Name Middle Name IVERSEN LESLIE** L **Street Address 1** Street Address 2 C/O ACADIA 3911 SORRENTO VALLEY BLVD PHARMACEUTICALS INC. City State/Province/Country ZIP/PostalCode SAN DIEGO **CALIFORNIA** 92121 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name Middle Name LESTER** J **KAPLAN Street Address 1** Street Address 2 C/O ACADIA 3911 SORRENTO VALLEY BLVD PHARMACEUTICALS INC. ZIP/PostalCode City State/Province/Country SAN DIEGO **CALIFORNIA** 92121 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): Middle Name Last Name First Name T **BORER MICHAEL Street Address 1 Street Address 2** C/O ACADIA 3911 SORRENTO VALLEY BLVD PHARMACEUTICALS INC. City **State/Province/Country** ZIP/PostalCode **CALIFORNIA** SAN DIEGO 92121 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name** First Name Middle Name **RASMUSSEN TORSTEN Street Address 1 Street Address 2** C/O ACADIA 3911 SORRENTO VALLEY BLVD PHARMACEUTICALS INC. ZIP/PostalCode City **State/Province/Country** SAN DIEGO **CALIFORNIA** 92121 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary): **Last Name First Name** Middle Name **GRAY** MARY ANN **Street Address 1 Street Address 2** C/O ACADIA 3911 SORRENTO VALLEY BLVD PHARMACEUTICALS INC. ZIP/PostalCode City State/Province/Country SAN DIEGO **CALIFORNIA** 92121 **Relationship:** Executive Officer X Director Promoter Clarification of Response (if Necessary):

**First Name** 

**Last Name** 

Middle Name

AASEN THOMAS H

Street Address 1

Street Address 2

3911 SORRENTO VALLEY BLVD

City State/Province/Country ZIP/PostalCode

SAN DIEGO CALIFORNIA 92121

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

MILLS ROGER G

Street Address 1 Street Address 2

3911 SORRENTO VALLEY BLVD

City State/Province/Country ZIP/PostalCode

SAN DIEGO CALIFORNIA 92121

Relationship: X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

BAITY GLENN F

Street Address 1 Street Address 2

3911 SORRENTO VALLEY BLVD

City State/Province/Country ZIP/PostalCode

SAN DIEGO CALIFORNIA 92121

**Relationship:** X Executive Officer Director Promoter

Clarification of Response (if Necessary):

Last Name First Name Middle Name

WELLS WILLIAM M

Street Address 1 Street Address 2

C/O ACADIA

PHARMACEUTICALS INC. 3911 SORRENTO VALLEY BLVD

City State/Province/Country ZIP/PostalCode

SAN DIEGO CALIFORNIA 92121

**Relationship:** Executive Officer X Director Promoter

Clarification of Response (if Necessary):

4. Industry Group

Agriculture Health Care Retailing

Banking & Financial Services Biotechnology Restaurants
Commercial Banking Health Insurance Technology
Insurance

Investing Hospitals & Physicians Computers

Investment Banking X Pharmaceuticals Telecommunications
Pooled Investment Fund Other Health Care Other Technology

Is the issuer registered as Manufacturing Travel

an investment company under the Investment Company

Real Estate Airports

Act of 1940? Commercial Lodging & Conventions

Yes No Construction Tourism & Travel Services

Other Banking & Financial Services REITS & Finance Other Travel

Business Services Residential Other

Energy Other Real Estate
Coal Mining

Electric Utilities

**Energy Conservation** 

**Environmental Services** 

Oil & Gas

Other Energy

### 5. Issuer Size

Revenue Range	OR	Aggregate Net Asset Value Range
No Revenues		No Aggregate Net Asset Value
\$1 - \$1,000,000		\$1 - \$5,000,000
\$1,000,001 - \$5,000,000		\$5,000,001 - \$25,000,000
\$5,000,001 - \$25,000,000		\$25,000,001 - \$50,000,000
\$25,000,001 - \$100,000,000		\$50,000,001 - \$100,000,000
Over \$100,000,000		Over \$100,000,000
X Decline to Disclose		Decline to Disclose
Not Applicable		Not Applicable

## 6. Federal Exemption(s) and Exclusion(s) Claimed (select all that apply)

Rule 504(b)(1) (not (i), (ii) or (iii)) Rule 504 (b)(1)(i) Rule 504 (b)(1)(ii) Rule 504 (b)(1)(iii)	Rule 505  X Rule 506  Securities Act Section Investment Company Section 3(c)(1)	Act Section 3(c) Section 3(c)(9)
	Section 3(c)(2)	Section 3(c)(10)
	Section 3(c)(3)	Section 3(c)(11)
	Section 3(c)(4)	Section 3(c)(12)
	Section 3(c)(5)	Section 3(c)(13)
	Section 3(c)(6)	Section 3(c)(14)
	Section 3(c)(7)	

# 7. Type of Filing

X New Notice Date of First Sale 2012-12-17 First Sale Yet to Occur Amendment

## 8. Duration of Offering

Does the Issuer intend this offering to last more than one year? Yes X No

9. Type(s) of Securities Offered (select all that apply)

X Equity
Debt
Tenant-in-Common Securities
X Option, Warrant or Other Right to Acquire Another Security
X Security to be Acquired Upon Exercise of Option, Warrant or Other Right to Acquire Security
Other Right to Acquire Security

Other (describe)

outer rught to riequite occurry

10. Business Combination Transaction

Is this offering being made in connection with a business combination transaction, such as Yes X No a merger, acquisition or exchange offer?

Clarification of Response (if Necessary):

11. Minimum Investment

Minimum investment accepted from any outside investor \$0 USD

12. Sales Compensation

Recipient Recipient CRD Number None

2347 JEFFERIES & COMPANY, INC.

(Associated) Broker or Dealer None (Associated) Broker or Dealer CRD Number None

JEFFERIES & COMPANY, INC. 2347

> **Street Address 1 Street Address 2**

520 MADISON AVE 16TH FL

State/Province/Country ZIP/Postal Code City

10022 **NEW YORK NEW YORK** 

State(s) of Solicitation (select all that apply) All States

Check "All States" or check individual States

Foreign/non-US

ILLINOIS NEW YORK MASSACHUSETTS

Recipient CRD Number None Recipient

7616 COWEN AND COMPANY, LLC

(Associated) Broker or Dealer CRD Number None (Associated) Broker or Dealer None

COWEN AND COMPANY, LLC 7616

> **Street Address 1** Street Address 2

599 LEXINGTON AVE 20TH FL

State/Province/Country ZIP/Postal Code City

**NEW YORK NEW YORK** 10022

State(s) of Solicitation (select all that apply) All States Foreign/non-US Check "All States" or check individual States

NEW YORK

**NEW JERSEY** 

CONNECTICUT

TEXAS

CALIFORNIA

NORTH CAROLINA

MASSACHUSETTS

### 13. Offering and Sales Amounts

**Total Offering Amount** \$86,385,000 USD or Indefinite

**Total Amount Sold** \$86,385,000 USD

Total Remaining to be Sold \$0 USD or Indefinite

Clarification of Response (if Necessary):

Includes amounts which may be received by the Company upon the exercise of outstanding warrants (assuming no cashless exercise).

14. Investors

Select if securities in the offering have been or may be sold to persons who do not qualify as accredited investors, and enter the number of such non-accredited investors who already have invested in the offering. Regardless of whether securities in the offering have been or may be sold to persons who do not qualify as accredited investors, enter the total number of investors who already have invested in the offering:

29	

### 15. Sales Commissions & Finder's Fees Expenses

Provide separately the amounts of sales commissions and finders fees expenses, if any. If the amount of an expenditure is not known, provide an estimate and check the box next to the amount.

Sales Commissions \$5,633,000 USD X Estimate

Finders' Fees \$0 USD Estimate

Clarification of Response (if Necessary):

Includes reimbursement of certain costs and fees.

16. Use of Proceeds

Provide the amount of the gross proceeds of the offering that has been or is proposed to be used for payments to any of the persons required to be named as executive officers, directors or promoters in response to Item 3 above. If the amount is unknown, provide an estimate and check the box next to the amount.

\$0 USD Estimate

Clarification of Response (if Necessary):

Signature and Submission

Please verify the information you have entered and review the Terms of Submission below before signing and clicking SUBMIT below to file this notice.

Terms of Submission

In submitting this notice, each issuer named above is:

- Notifying the SEC and/or each State in which this notice is filed of the offering of securities described and undertaking to furnish them, upon written request, in the accordance with applicable law, the information furnished to offerees.\*
- Irrevocably appointing each of the Secretary of the SEC and, the Securities Administrator or other legally designated officer of the State in which the issuer maintains its principal place of business and any State in which this notice is filed, as its agents for service of process, and agreeing that these persons may accept service on its behalf, of any notice, process or pleading, and further agreeing that such service may be made by registered or certified mail, in any Federal or state action, administrative proceeding, or arbitration brought against the issuer in any place subject to the jurisdiction of the United States, if the action, proceeding or arbitration (a) arises out of any activity in connection with the offering of securities that is the subject of this notice, and (b) is founded, directly or indirectly, upon the provisions of: (i) the Securities Act of 1933, the Securities Exchange Act of 1934, the Trust Indenture Act of 1939, the Investment Company Act of 1940, or the Investment Advisers Act of 1940, or any rule or regulation under any of these statutes, or (ii) the laws of the State in which the issuer maintains its principal place of business or any State in which this notice is filed.
- Certifying that, if the issuer is claiming a Rule 505 exemption, the issuer is not disqualified from relying on Rule 505 for one of the reasons stated in Rule 505(b)(2)(iii).

Each Issuer identified above has read this notice, knows the contents to be true, and has duly caused this notice to be signed on its behalf by the undersigned duly authorized person.

For signature, type in the signer's name or other letters or characters adopted or authorized as the signer's signature.

Issuer	Signature	Name of Signer	Title	Date
ACADIA PHARMACEUTICALS INC	/S/ GLENN F. BAITY	GLENN F. BAITY	VP, GENERAL COUNSEL	2012-12-21

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.

\* This undertaking does not affect any limits Section 102(a) of the National Securities Markets Improvement Act of 1996 ("NSMIA") [Pub. L. No. 104-290, 110 Stat. 3416 (Oct. 11, 1996)] imposes on the ability of States to require information. As a

result, if the securities that are the subject of this Form D are "covered securities" for purposes of NSMIA, whether in all instances or due to the nature of the offering that is the subject of this Form D, States cannot routinely require offering materials under this undertaking or otherwise and can require offering materials only to the extent NSMIA permits them to do so under NSMIA's preservation of their anti-fraud authority.